Human Cancer Antigen 242 CLIA Kit

Chemiluminescence Immunoassay for the quantitative determination of Cancer Antigen 242 in human serum

REF SKT-068 € (VD) * \$\frac{\text{\$\tilde{V}\$}}{\tilde{V}}_{100,150} \frac{\text{\$\tilde{V}}^2}{\tilde{V}} (100,150)

INTENDED USE

Human Cancer Antigen 242 CLIA Kit is a Chemiluminescence Immunoassay (CLIA) intended for the quantitative measurement of human Cancer Antigen 242 in serum.

For in-vitro diagnostics purposes only

SUMMARY OF PHYSIOLOGY

The kit is used for clinical in vitro quantitative detection of cancer antigen 242 concentrations in human serum.

Cancer antigen 242 is an important serum tumor marker for the diagnosis of pancreatic cancer⁴, and it is superior to CA19-9 in the diagnosis of pancreatic cancer because of its higher specificity, and it may be useful in the screening of localized or resectable tumours⁵⁻⁶.

ASSAY PRINCIPLE

The Human Cancer Antigen 242 CLIA Kit is designed, developed, and produced for the quantitative measurement of human CA 242 level in serum samples.

The CA 242 assay is a two-site sandwich assay to determination the level of CA 242.

Assay calibrators, controls, or patient serum samples are added directly to a reaction vessel together with magnetic particles antibody. The magnetic particles capture the CA 242 in the form of "magnetic particles—CA 242 antibody—CA 242—acridinium ester CA 242 antibody". Materials bound to the solid beads are held in a magnetic field while unbound materials are washed away. Then trigger solutions are added to the reaction vessel, and light emission is measured with the ECL100 or ECL 25 analyzer. The relative light units (RLU) are proportional to the concentration of a CA 242 in the sample. The amount of analyte in the sample is determined from a stored, multi-point calibration curve and reported in serum CA 242 concentration.

REAGENTS: PREPARATION AND STORAGE

This test kit must be stored at $2-8^{\circ}$ C upon receipt. For the expiration date of the kit refer to the label on the kit box. All components are stable until this expiration date. It can be stored for 1 month at 2° C -8° C after kit opening.

1. CA 242 Magnetic Particle Solution (06801)

Qty: 6.0 mL (100/kit), 8.5 mL (150/kit)

Storage: $2 - 8^{\circ}C$ Preparation: Ready to Use

2. Acridinium ester CA 242 antibody(06803)

Qty: 6.0 mL (100/kit),8.5 mL (150/kit)

Storage: $2 - 8^{\circ}$ C Preparation: Ready to Use

3. CA 242 Calibrators (06806-06808)

Qty: 3 x vials Storage: $2 - 8^{\circ}$ C Preparation: Ready to Use

After the first use, it is recommended to storage at 2 - 8°C and can be used within one month. Do not freeze.

4.CA 242 Controls(06809-06810)

Qty: 2 x vials Storage: 2 – 8°C Preparation: Ready to Use

After the first use, it is recommended to storage at $2 - 8^{\circ}C$ and can be used within one month. Do not freeze.

SAFETY PRECAUTIONS

The reagents must be used in a professional laboratory environment and are for in vitro diagnostic use. Source material which contains reagents of bovine serum albumin was derived in New Zealand. It was obtained only from healthy donor animals maintained under veterinary supervision and found free of contagious diseases. Wear gloves while performing this assay and handle these reagents as if they were potentially infectious. Avoid contact with reagents containing hydrogen peroxide. Do not get in eyes, on skin, or on clothing. Do not ingest or inhale fumes. On contact, flush with copious amounts of water for at least 15 minutes. Exercise Good Laboratory Practices.

MATERIALS REQUIRED BUT NOT PROVIDED

- ECL100 Immunoassay Analyzer (ECL100) or ECL25 Immunoassay Analyzer (ECL25)
- CL011 Cuvettes (for ECL100) or CL010 Cuvettes (for ECL25)
- 3. EDI™ Wash Reagent (P-594)
- 4. EDI™ Trigger Solutions A and B (P-595A, P-595B)

The instrument must operate using materials supplied by Epitope Biotechnology, Co.,Ltd. or Epitope Diagnostics, Inc. When materials are sourced from third-party suppliers are being used, Epitope Biotechnology,Co.,Ltd. and Epitope Diagnostics, Inc. takes no responsibility of the validity for obtained results. Materials are available to purchase from Epitope Biotechnology,Co.,Ltd. and Epitope Diagnostics, Inc. Please contact your distributor for more information.

SPECIMEN COLLECTION AND PREPARATION

- 1. Blood sample should be collected under sterile conditions.
- 2. For human serum samples, other body fluids and samples may not get accurate results.
- 3. Clinical samples should be tested within 2 hours after collection. If the measurement cannot be completed within 2 hours, please store under the following conditions:
 - Store at low temperature and away from light (2°C~8°C) for 2 days.
 - Store at -20°C or below for 6 months.
 - Freeze and thaw only once.
- 4. Avoid heat-inactivated samples. Mixed, contaminated and hemolysis samples should be discarded.
- 5. Samples should be restored to room temperature before testing. Samples stored in freezer should be completely melted, and mixed evenly before use. Due to possible volatilization, samples, calibrators and controls on the ECL platform should be tested within 2 hours.

6. Some substances in the samples will interfere with the test results. The common interfering substances and maximum allowable concentrations are as follows:

bilirubin: 50 mg/dL triglyceride: 2000 mg/dL hemoglobin: 500 mg/dL biotin: 100nmol/L

For patients receiving high-dose biotin therapy (5 mg/day), samples must be collected 8 hours after taking the last dose of biotin.

7. A single assay of this item requires 15 μ L sample. This quantity does not include the amount of dead volume in the sample container, the capacity required for retesting, and other measurement items. For the definition of minimum required sample size, refer to the equipment manual.

CALIBRATION

An active calibration curve is required for all tests. Calibration is required for the first time use of a reagent lot and every 14 days thereafter or when either kit control is out of range. Refer to appropriate system manuals for configuring calibrators.

QUALITY CONTROL

The characteristics of patient samples are simulated through controls and are critical to validate the performance of CLIA assays due to the random access format. Use of controls is left to the discretion of the user based on good laboratory practices, requirements, and applicable laws. We suggest performing a control test once every day. Quality control results that do not fall within acceptable ranges may indicate invalid test results.

ASSAY PROCEDURE

 Reagents from different kit lot numbers should not be combined or interchanged. Make sure that there are no air bubbles in any reagents, calibrator and control vials.

2. Reagent Preparation

- 2.1 Remove reagent cartridges from packaging and replace the solid caps with the provided soft caps for ECL100. For ECL25, carefully remove the aluminum foil seal on each on each container on the cartridges and insert soft caps.
- 2.2 For the ECL100, take out the Magnetic Particle bottle make sure to roll between hands and gently but thoroughly mix until the magnetic particle solution is homogenous. The solution should be uniform with no clumps of magnetic particles visible; this step is vital for assay performance. For ECL25, mix the magnetic beads by moving back and forth the bottom part of the cartridge at upright position. Make sure to look inside the cartridge until the solution is uniform with no clumps of magnetic particles visible and no air bubbles. Recap the bottle. Open the top soft cap of all reagent bottles, leaving only the hollow soft rubber. The reagents are now ready to be loaded into the ECL100 or ECL 25 for calibration.

3. Assay Program

The following table illustrates the protocol used by the ECL100 or ECL25 for instrument operation.

Component	Quality Control Hole (µL)	Sample Hole (µL)
CA 242 Controls(06809-06810)	15	-
Samples	-	15
CA 242 Magnetic Particle Solution (06801)	50	50
Acridinium ester CA 242 antibody(06803)	50	50

FOR REFERENCE USE ONLY

Incubate at 37°C for 15 minutes			
Wash the reaction cuvette 3 times with wash reagent.			
Trigger Solution A (P-595)	100-200	100-200	
Trigger Solution B (P-595)	100-200	100-200	

NOTE FOR ASSAY PROCEDURE

Reagents from different kit lot numbers should not be combined or interchanged. Make sure that there is no air bubble in any reagents, calibrator and control vials.

All the reagents in this kit are ready-to-use. Different lots of the same reagents are not inter-changeable and must not be used.

Please read the reagent instructions and equipment instructions carefully before using this kit and perform the test according to relevant requirements. When reagents are loaded, the equipment will automatically stir the magnetic particles to resuspend them. Allow the regent to mix for minimum 15 min before starting the assay program.

INTERPRETION OF RESULTS

- 1. The default unit for the Cancer Antigen 242 project is U/mL
- 2. Due to methodological differences or antibody specificity, there may be deviations between the test results of reagents from different manufacturers. Therefore, direct comparisons should not be made to avoid false interpretation.
- 3. When the concentration of CA 242 in the sample exceeds 200.0 U/mL the sample can be diluted before measurement.
- 4. When the sample concentration of Cancer Antigen 242 is lower than the detection lower limit, the test result can be reported as < 0.500 U/mL. When the sample concentration is higher than the detection upper limit, it can be reported as > 200.0 U/mL.

EXPECTED VALUES

Normal reference value<20U/mL.

This range is determined by the 95 percentile of CA 242 serum concentrations obtained by measurement of CA 242 with this assay from 502 healthy donors

Note: each Laboratory is recommended to determine and establish its own reference range with local population.

LIMITATIONS OF THE PROCEDURE

- This product is for use on the ECL100 Immunoassay Analyzer or ECL 25 Immunoassay Analyzer only. Refer to the appropriate system manuals and/or Help system for a specific description of installation, start-up, operation, system performance, instructions, calibration, precautions, hazards, maintenance, and troubleshooting.
- Reagents from different kit lot numbers should not be combined or interchanged.
- Test results obtained from the proposed kit should not be served as a sole basis for clinical diagnosis or patient management.
- 4. If the test sample result is higher than the upper limit of the calibration curve, it is recommended to re-measure after dilution according to a certain ratio. The measured value is recalculated according to the dilution ratio to ensure the accuracy of the result.

SKT-068/CE, IVD/V2/2022-12 Page **2** of **3**

FOR REFERENCE USE ONLY

PERFORMANCE CHARACTERISTICS

1. Hook Effect:

The assay showed no hook effect up to 10000U/mL.

2. Limit of Detection(LoD):

≤0.500 U/mL.

3.Linearity:

- 0.500 U/mL to 200.0U/mL,
- Linearity correlation coefficient R ≥0.990.

4.Accuracy:

Relative deviation within \pm 10%.

5.Precision:

- Intra-assay repeatability: CV≤8%;
- Inter-assay reproducibility: CV≤15%.

NOTES

- Read the instructions carefully and gently but thoroughly mix the reagent before use. Remove any air bubbles before loading the reagents onto the equipment.
- Keep the reagent in the storage conditions indicated 2. in this IFU and on the reagent label. Do not freeze reagents
- 3. Avoid contact with skin, eyes and mucous membrane. Upon contact, flush the area with clean water immediately.
- All patient samples must be treated as potential infectious material.
- Components in different kits cannot be mixed.
- All waste must be disposed of in compliance with local regulations and laws.

WARRANTY

This product is warranted to perform as described in its labeling and literature when used in accordance with all instructions. Epitope Biotechnology Co,Ltd and its distributors DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, and in no event shall Epitope Biotechnology Co,Ltd.. be liable for consequential damages. Replacement of the product or refund of the purchase price is the exclusive remedy for the purchaser. This warranty gives you specific legal rights and you may have other rights, which vary from state to state.

REFERENCE

1.Chan, S. H., Lindholm, L., Wong, L., &Oon, C. J. (1985). Tumour markers in hepatocellular carcinoma in Singaporean Chinese.Tumour Marker Antigen, Holmgren, J.(ed.), 106. 2.Gui, J. C., Yan, W. L., & Liu, X. D. (2014). CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a metaanalysis. Clinical and experimental medicine, 14(2), 225-233. 3. Haglund, C., Lundin, J., Kuusela, P., & Roberts, P. J. (1994). CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. British journal of cancer, 70(3), 487. 4.Zhang, Y., Yang, J., Li, H., Wu, Y., Zhang, H., & Chen, W. (2015). Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis. International journal of clinical and experimental medicine, 8(7), 11683. 5.Kawa, S., Tokoo, M., Hasebe, O., Hayashi, K., Imai, H., Oguchi, H., ... & Homma, T. (1994). Comparative study of CA242 and CA19-9 for

the diagnosis of pancreatic cancer. British journal of cancer, 70(3),

6.Ni, X. G., Bai, X. F., Mao, Y. L., Shao, Y. F., Wu, J. X., Shan, Y., ... &Xu, D. K. (2005). The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. European Journal of Surgical Oncology (EJSO), 31(2), 164-169.

TECHNICAL ASSISTANCE AND CUSTOMER SERVICE

For technical assistance or to place an order, please contact Epitope Diagnostics, Inc. in USA at +1 858-693-7877 or email to cs@epitopediagnostics.com



Epitope Biotechnology, Co.,Ltd. 599 Yazhong Rd. 3-4F, Jiaxing Zhejiang 314006, China



This product is marketed by **Epitope Diagnostics, Inc.** 7110 Carroll Rd San Diego, CA 92121 United States www.epitopediagnotics.com



MDSS GmbH Schiffgraben 41, 30175 Hannover, Germany

GLOSSARY OF SYMBOLS (EN 980/ISO 15223)



European Conformity





Read Instructions before Use





Manufacturer





Authorized Representative in Europe





SKT-068/CE, IVD/V2/2022-12 Page 3 of 3